Sílvia Almeida, is the CSO of AccelBio since September 2023, bringing two decades of experience bridging academia and the pharmaceutical landscape. Before joining AccelBio, Sílvia worked at Charles River Laboratories Ireland Ltd (CRL-IRE), initially as a Virologist, being responsible for leading the GMP implementation of the Biosafety Department.
Progressing to Department Manager and in vitro Scientific Manager, Sílvia expanded the department’s capabilities, overseeing method transfers, validations, and development. In her recent role as Head of in vitro Scientific Development and Business Strategies, she contributed to departmental strategy decisions, collaborated with global staff, and played a pivotal role in implementing new technologies.
With a decade of lecturing experience, Sílvia also served as a Foreign Visiting Professor for two years at the Federal University of Espirito Santo, Brazil, lecturing on Immunology, Molecular Biology, and Virology.
Sílvia expertise in virology and immunology stems from a six-year postdoctoral tenure at iMM, focusing on iNKT regulatory cells and follicular helper T cells.
Silvia holds a Ph.D. from Instituto Gulbenkian de Ciencia (IGC) – Universidade Nova de Lisboa (UN), specializing in manipulating the immune system by key viral genes in an in vivo cell-restricted context.